(688443)"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688443 · · 14 pages · Chinese
Summary by 6ix AI
The report confirms that the financial data presented is accurate and complete, with the board of directors taking legal responsibility for its contents. Key financial highlights include significant increases in revenue and net profit compared to the same period last year, driven by strong sales of new products and licensing agreements. The report also notes ongoing progress in several research projects and regulatory approvals for new drug applications.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Chongqing Genrix Biopharmaceutical Co., Ltd. on 6ix
Earlier from Chongqing Genrix Biopharmaceutical
- (688443)"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Acceptance of the Marketing Application for Telikibart Injection for the Indication of Chronic Spontaneous Urticaria
- (688443)"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Telikibart Injection for the Indication of Chronic Rhinosinusitis with Nasal Polyps
- (688443)"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Change of Signing Certified Public Accountant
- Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Chongqing Jurisdiction and Semi-annual Performance Briefing
- Announcement on Convening the 2026 Semi-annual Performance Briefing
Later from Chongqing Genrix Biopharmaceutical
- (688443)"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Inclusion of Telikibart Injection in the Priority Review Drug List
- (688443)"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Convening the Q3 2026 Performance Briefing
Follow Chongqing Genrix Biopharmaceutical into a list and get an email when it puts out news.
Follow Chongqing Genrix Biopharmaceutical